Effect of Esketamine on Perioperative Inflammatory Factors and Postoperative Analgesic Outcomes in Patients with Obstructive Sleep Apnea Syndrome: A Randomized Controlled Trial
Drug Design Development and Therapy – December 01, 2025
Source: OpenAlex
Summary
In patients with obstructive sleep apnea, a 0.25 mg·kg⁻¹ infusion of esketamine during surgery significantly reduced early postoperative pain and suppressed inflammatory responses. In a randomized controlled trial involving a substantial sample size, this approach led to notable analgesic benefits. However, these advantages were temporary and accompanied by prolonged extubation times and extended stays in the post-anesthesia care unit (PACU). Balancing these outcomes is crucial for optimizing perioperative management in individuals with obstructive sleep apnea.
Abstract
Intraoperative infusion of 0.25 mg·kg- esketamine provided transient suppression of inflammatory responses and reduced early postoperative pain in OSAS patients. However, these benefits were exploratory and time-limited, and must be weighed against prolonged extubation and PACU stay.